JDRF has extended a jointly-funded research programme with Johnson & Johnson (which has the diabetes-specific Lifescan and Animas brands in the UK) focused on developing therapies to promote beta cell survival and function in people with type 1 diabetes.
The partnership with Johnson & Johnson began in 2009, but there are now plans to double the number of beta cell projects being funded. Research grant proposals will be invited from academia and medical research institutions for one- or two-year projects. The applications will be reviewed by a combined committee from JDRF and the Johnson & Johnson Corporate Office of Science and Technology.
Dr Eleanor Kennedy, Head of Research Communication at JDRF said, “This research programme is a great example of JDRF working with industry to prioritise early-stage diabetes research. With this support, we can ensure new technologies and treatments reach people with type 1 as quickly as possible.”
Preserving beta cell function has a range of potential benefits including reduced insulin requirements, slower disease progression, and reduced risk of hypos and complications later in life. The joint program currently funds research to identify specific molecules involved in beta cell survival and lifespan.
